Agenus Reports 48% 3-Year OS in Ovarian Cancer Combo
Agenus reported an estimated 48% three-year overall survival in 35 evaluable patients in its Phase 1b C-800-01 ovarian cancer cohort using botensilimab plus balstilimab.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.